Fujifilm Kyowa Kirin JV lines up bevacizumab as next biosimilar target
This article was originally published in Scrip
Fujifilm Kyowa Kirin Biologics, the equally owned joint venture between Japan's Fujifilm and Kyowa Hakko Kirin, has unveiled Roche/Genentech's big-selling anticancer antibody Avastin (bevacizumab) as the next project in its growing pipeline of biosimilars.
You may also be interested in...
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.